06:06 GMT21 October 2020
Listen Live
    Get short URL

    On Tuesday, the US Food and Drug Administration (FDA) issued new non-binding guidelines that encourage COVID-19 vaccine manufacturers to monitor volunteers for at least two months after their last injection of a drug in order to ensure the vaccine's safety and efficiency.

    President Donald Trump has lashed out at the US Food and Drug Administration (FDA) over its new set of coronavirus vaccine guidelines, which he claimed ride roughshod over the process of pre-election inoculation.

    On Wednesday, POTUS tweeted that the new rules "make it more difficult" for the FDA "to speed up vaccines for approval before Election Day", describing the guidelines as "just another political hit job" and tagging FDA Commissioner Stephen Hahn in his post.

    The remarks followed The New York Times quoting unnamed sources as saying on Tuesday that White House Chief of Staff Mark Meadows has been blocking the guidelines since 21 September, when the document was submitted by the FDA to the Office of Management and Budget for review.  

    The new set of guidelines, which is a non-binding document outlining recommendations for pharmaceutical companies, suggests that trial subjects should be observed for at least two months after the last injection of a drug to ensure its safety and efficiency. The guidelines were issued by the FDA earlier on Tuesday.

    This was preceded by Trump saying in late September that the guidelines have "to be approved by the White House", referring to the document as "a political move".

    In a separate development late last month, POTUS claimed during the first presidential debate that the United States was "weeks away" from obtaining a coronavirus vaccine, adding that his administration has done a "great job" concerning the COVID-19 pandemic.

    He also said that the vaccine could be made available sooner if not for political interference and accused Democratic presidential nominee Joe Biden of sowing distrust in potential vaccines.

    Earlier, Trump pledged that 100 million doses of the vaccine would be distributed throughout the United States by the end of the year. He has repeatedly vowed that a vaccine would be available for distribution before the US presidential election on 3 November.

    Democrats, in turn, accuse Trump of rushing the development of the vaccine in order to obtain it before the November election, something that they claim may affect the drug's effectiveness.


    ‘Momentous News’: FDA Approves Launch of Phase 1 Trial for Potential HIV Cure
    Trump's Chief of Staff Says President Wants FDA to 'Feel the Heat' to Quicken Vaccine Development
    Trump Says Plasma Treatment for COVID19 Approved by FDA Expected to Reduce Mortality by 35%
    development, vaccine, COVID-19, coronavirus, Donald Trump, Food and Drug Administration (FDA), United States
    Community standardsDiscussion